UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis
Author:
Funder
Karolinska Institutet
Kaleyde Pharmaceuticals AG
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Drug Discovery,Molecular Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00109-019-01794-w.pdf
Reference31 articles.
1. Morrison JC, Van Buskirk EM (1983) Anterior collateral circulation in the primate eye. Ophthalmology 90:707–715
2. Dreyfuss JL, Giordano RJ, Regatieri CV (2015) Ocular angiogenesis. J Ophthalmol 2015:892043
3. Kovacs K, Marra KV, Yu G, Wagley S, Ma J, Teague GC, Nandakumar N, Lashkari K, Arroyo JG (2015) Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Invest Ophthalmol Vis Sci 56:6523–6530
4. Gartner S, Henkind P (1978) Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol 22:291–312
5. Jeong YC, Hwang YH (2016) Etiology and features of eyes with rubeosis iridis among Korean patients: a population-based single center study. PLoS One 11:e0160662. https://doi.org/10.1371/journal.pone.0160662
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mitigation of human iris angiogenesis through uPAR/LRP‐1 interaction antagonism in an organotypic ex vivo model;The FASEB Journal;2024-03-07
2. Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug;International Journal of Biological Macromolecules;2023-01
3. Pharmacokinetics of the Urokinase Receptor-Derived Peptide UPARANT After Single and Multiple Doses Administration in Rats;European Journal of Drug Metabolism and Pharmacokinetics;2020-10-21
4. Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy;Journal of Molecular Medicine;2020-09-17
5. The uPAR System as a Potential Therapeutic Target in the Diseased Eye;Cells;2019-08-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3